Matching articles for "Latuda"
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • April 1, 2024; (Issue 1699)
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Lumateperone (Caplyta) for Bipolar Depression
The Medical Letter on Drugs and Therapeutics • August 8, 2022; (Issue 1656)
The oral second-generation antipsychotic drug
lumateperone (Caplyta – Intra-Cellular Therapies),
which was approved by the FDA in 2020 for treatment
of schizophrenia, is now approved for use...
The oral second-generation antipsychotic drug
lumateperone (Caplyta – Intra-Cellular Therapies),
which was approved by the FDA in 2020 for treatment
of schizophrenia, is now approved for use as
monotherapy or as an adjunct to lithium or valproate
for treatment of depressive episodes associated with
bipolar I or II disorder in adults.
Lumateperone (Caplyta) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • July 27, 2020; (Issue 1603)
The FDA has approved lumateperone (Caplyta —
Intracellular Therapies), an oral second-generation
antipsychotic, for once-daily treatment of schizophrenia
in adults. It is the 13th second-generation...
The FDA has approved lumateperone (Caplyta —
Intracellular Therapies), an oral second-generation
antipsychotic, for once-daily treatment of schizophrenia
in adults. It is the 13th second-generation antipsychotic
drug to be approved by the FDA for this indication.
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • August 15, 2016; (Issue 1501)
Bipolar disorder is characterized by intermittent
episodes of mania and/or depression. Even with
maintenance treatment, recurrences of manic or (more
frequently) depressive episodes are common. Some of
the...
Bipolar disorder is characterized by intermittent
episodes of mania and/or depression. Even with
maintenance treatment, recurrences of manic or (more
frequently) depressive episodes are common. Some of
the drugs and dosages recommended here have not
been approved by the FDA for use in bipolar disorder.
Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder
The Medical Letter on Drugs and Therapeutics • April 25, 2016; (Issue 1493)
The FDA has approved cariprazine (Vraylar – Actavis), an
oral, once-daily, second-generation antipsychotic, for treatment
of schizophrenia and for acute treatment of manic or
mixed episodes associated with...
The FDA has approved cariprazine (Vraylar – Actavis), an
oral, once-daily, second-generation antipsychotic, for treatment
of schizophrenia and for acute treatment of manic or
mixed episodes associated with bipolar I disorder.
Brexpiprazole (Rexulti) for Schizophrenia and Depression
The Medical Letter on Drugs and Therapeutics • August 17, 2015; (Issue 1475)
The FDA has approved the oral, once-daily, second-generation
antipsychotic brexpiprazole (Rexulti –
Otsuka/Lundbeck) for treatment of schizophrenia
and as an adjunct to antidepressants for treatment
of...
The FDA has approved the oral, once-daily, second-generation
antipsychotic brexpiprazole (Rexulti –
Otsuka/Lundbeck) for treatment of schizophrenia
and as an adjunct to antidepressants for treatment
of major depressive disorder (MDD). Aripiprazole
(Abilify), a structurally similar second-generation
antipsychotic also comarketed by Otsuka (with BMS),
recently became available generically.
Drugs for Psychiatric Disorders
The Medical Letter on Drugs and Therapeutics • June 1, 2013; (Issue 130)
Drugs are not the only treatment for psychiatric illness.
Psychotherapy remains an important component
in the management of these disorders, and cognitive
behavioral therapy (CBT) can be used for many...
Drugs are not the only treatment for psychiatric illness.
Psychotherapy remains an important component
in the management of these disorders, and cognitive
behavioral therapy (CBT) can be used for many of
them as well. Electroconvulsive therapy (ECT) has a
long history of efficacy and safety when drugs are
ineffective or cannot be used.
Lurasidone (Latuda) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • February 21, 2011; (Issue 1358)
The FDA has approved lurasidone (Latuda - Sunovion), a new second-generation antipsychotic,
for oral treatment of schizophrenia in...
The FDA has approved lurasidone (Latuda - Sunovion), a new second-generation antipsychotic,
for oral treatment of schizophrenia in adults.